Sarepta Therapeutics Announces Second Quarter 2017 Financial Results and Recent Corporate Developments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Sarepta Therapeutics (SRPT) PT Raised to $33 at Morgan Stanley
July 20, 2017 9:16 AM EDTMorgan Stanley raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $33.00 (from $31.00) while maintaining a Equalweight rating.
... MoreSarepta Therapeutics (SRPT) PT Raised to $69 at Cowen Following 'Beat and Raise'
July 20, 2017 6:07 AM EDTCowen analyst Ritu Baral raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $69.00 (from $62.00) while maintaining a Outperform rating following a solid beat and raise for Exondys 51 revenues.
Baral sees continued progress with both prescribers and payors... More
